📄 What This Document Is

This is an 8-K filing from Profound Medical, which is a special report to the SEC used to announce major company news. In this case, it's sharing a press release about their technology being featured at a major medical conference. The news isn't financial results; it's about clinical validation and market awareness.

🏢 What The Company Does

👉 In simple terms, Profound Medical makes robots that use MRI scans and sound waves to destroy diseased tissue without surgery. They are a commercial-stage medical device company focused on "incision-free" therapies. Their main products are the TULSA-PRO® system for prostate disease (like cancer and enlargement) and the Sonalleve® system for conditions like bone tumors and uterine fibroids. Think of them as a high-tech surgical alternative.

🗓️ The Conference Showcase

Profound's TULSA-PRO system will be a major topic at the 2026 Society of Interventional Radiology (SIR) meeting in Toronto from April 11-15.

• When: A dedicated session called "Men's Health 1" on April 12, 2026, from 3:00-4:30 p.m. EDT.
• What: Five oral presentations will feature the TULSA procedure, covering topics like treating cancer at the prostate's apex, recurrent cancer, and a major "2026 Featured Abstract" on automated prostate segmentation.
• Big One: A presentation on the Level 1 CAPTAIN trial, which is a randomized controlled trial comparing TULSA directly to robotic prostatectomy (surgery). This is the gold-standard type of study for proving a treatment's effectiveness.

🚀 Why This Matters

Presenting at a major, respected medical conference like SIR is a key way to build credibility with doctors (who are their customers). 👉 For investors, this signals: 1) Growing clinical evidence for their technology, 2) Endorsement from leading physicians at top institutions (like Mayo Clinic and UCLA), and 3) A strategic push to make TULSA a mainstream treatment option. The featured abstract selection is a particularly strong nod from the medical community.

🧪 Pipeline & Clinical Evidence

The filing highlights the CAPTAIN trial, a major post-market study. This isn't just research; it's data generated after the product is already for sale, which is crucial for convincing more hospitals to adopt the technology. The presentations will share real-world doctor experiences and systematic reviews, building a stronger evidence package than what the company alone could produce.

🔮 What's Next & The Company's View

The CEO, Arun Menawat, stated this conference presence comes at an "opportune time." He believes MRI-guided procedures like TULSA are "poised to transform" prostate care. 👉 The strategy for 2026 is to build on this momentum by highlighting the CAPTAIN trial data and showcasing physician experiences to accelerate awareness and acceptance of the TULSA procedure as a standard treatment.

⚖️ The Big Picture

👍 Strengths: Cutting-edge, minimally invasive technology with a growing portfolio of clinical data presented by independent experts. The procedure offers clear patient benefits (no incisions, quick recovery, fewer side effects). ⚠️ Risks: Adoption by doctors and hospitals can be slow. The company needs the clinical evidence from trials like CAPTAIN to convince the market to switch from traditional surgery or radiation. Competition in the medical device space is always intense.

🧠 The Analogy

Think of Profound's TULSA-PRO like a smart home system for the human body. Instead of major construction (surgery), it uses real-time sensors (MRI) to guide a precise tool (ultrasound) to fix a specific problem (diseased prostate tissue) without touching the surrounding delicate wiring (nerves controlling urinary and sexual function). The conference is like the system getting a glowing review from top tech magazines.

📇 Key Contacts & People

Investor Relations: Stephen Kilmer [email protected] T: 647.872.4849

Public Relations: Susan Thomas [email protected] T: 619.540.9195

Presenting Physicians (Named in the Release):

• Joseph J. Busch, Jr., M.D. (Busch Center)
• Arsalan Nadeem, MBBS (Northwestern University)
• Steven S. Raman, M.D., FASR, FSIR (UCLA)
• David A. Woodrum, M.D., Ph.D. (Mayo Clinic)
• Christopher Ingraham, M.D. & Juan Javier-Desloges, M.D. (UCSD School of Medicine)

🧩 Final Takeaway

Profound is in a growth and validation phase, using a major medical conference to showcase expanding clinical evidence from independent doctors. This is a key step to move its robotic, incision-free prostate treatment from an innovative option to a mainstream standard of care.